Open AccessPlatelet Activation and Platelet–Leukocyte Aggregates in Type I Diabetes Mellitus
Author(s) -
Asmaa M Zahran,
Omnia ElBadawy,
Ismail Lotfy Mohamad,
Deiaaeldin M Tamer,
Safwat M. Abdel-Aziz,
Khalid I Elsayh
Publication year - 2018
Publication title -
clinical and applied thrombosis/hemostasis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.643
H-Index - 53
eISSN - 1938-2723
pISSN - 1076-0296
DOI - 10.1177/1076029618805861
Subject(s) - platelet , cd36 , medicine , platelet activation , hyperlipidemia , endocrinology , diabetes mellitus , monocyte , glycated hemoglobin , type 1 diabetes , type 2 diabetes mellitus , type 2 diabetes , receptor
Hyperglycemia alone may not explain the increased risk of cardiovascular diseases (CVDs) in patients with type 1 diabetes (T1D) compared with type 2. This study emphases on the evaluation of some platelet activity markers in patients with T1D, with relevance to some metabolic disorders as hyperlipidemia and hyperglycemia. This study was performed on 35 patients with T1D and 20 healthy controls. All participants were subjected to full history taking, clinical examination and assay of glycated hemoglobin (HbA 1c ), and lipid profile. The expression of CD62P and CD36 on platelets and the frequency of platelet–monocyte, and platelet–neutrophil aggregates were assessed by flow cytometry. Patients showed significantly higher expression of CD62P and CD36 than the control group. Platelets aggregates with monocytes were also higher among patients than the control group. Levels of CD36 + platelets, CD62P + platelets, and platelet–monocyte aggregates revealed significant correlations with the levels of HbA 1c , total cholesterol, low-density lipoprotein, and triglycerides. Hyperlipidemia and hyperglycemia accompanying T1D have a stimulatory effect on platelet activation which probably makes those patients vulnerable to CVD than nondiabetics.